Mapping the availability, price, and affordability of antiepileptic drugs in 46 countries

Epilepsia

Volumn 53, Issue 6, 2012, Pages 962-969

  Cameron, Alexandra ^a,b   Bansal, Amit ^a,c   Dua, Tarun ^a   Hill, Suzanne R ^a   Moshe, Solomon L ^d   Mantel Teeuwisse, Aukje K ^b   Saxena, Shekhar ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UTRECHT UNIVERSITY   (Netherlands)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Affordability; Antiepileptic drugs; Availability; Developing countries; Epilepsy; Generics; Medicines; Originator brands; Pharmaceuticals; Price; Treatment gap

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; DIAZEPAM; GENERIC DRUG; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID;

ARTICLE; DRUG BIOAVAILABILITY; DRUG COST; EPILEPSY; GOVERNMENT; HEALTH CARE FACILITY; HEALTH CARE POLICY; HEALTH SURVEY; HUMAN; LOWEST INCOME GROUP; ORGANIZATION AND MANAGEMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PURCHASING; SALARY; WORKER; WORLD HEALTH ORGANIZATION;

ANTICONVULSANTS; DEVELOPING COUNTRIES; EPILEPSY; HEALTH SERVICES ACCESSIBILITY; HEALTH SURVEYS; HUMANS; WORLD HEALTH;

EID: 84861792860     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2012.03446.x     Document Type: Article

References (32)

1. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R,. (2009) Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet 373: 240-249.
2. Cameron A, Roubos I, Ewen M, Mantel-Teeuwisse AK, Leufkens HG, Laing RO,. (2011) Differences in the availability of medicines used for chronic and acute conditions in the public and private sectors of developing countries. Bull World Health Organ 89: 412-421.
3. Chisholm D,; WHO-CHOICE. (2005) Cost-effectiveness of first-line antiepileptic drug treatments in the developing world: a population-level analysis. Epilepsia 46: 751-759.
4. Chomba EN, Haworth A, Mbewe E, Atadzhanov M, Ndubani P, Kansembe H, Birbeck GL,. (2010) The current availability of antiepileptic drugs in Zambia: implications for the ILAE/WHO "out of the shadows" campaign. Am J Trop Med Hyg 83: 571-574.
5. Collins PY, Patel V, Joestl SS, March D, Insel TR, Daar AS,; Scientific Advisory Board and the Executive Committee of the Grand Challenges on Global Mental Health, Anderson W, Dhansay MA, Phillips A, Shurin S, Walport M, Ewart W, Savill SJ, Bordin IA, Costello EJ, Durkin M, Fairburn C, Glass RI, Hall W, Huang Y, Hyman SE, Jamison K, Kaaya S, Kapur S, Kleinman A, Ogunniyi A, Otero-Ojeda A, Poo MM, Ravindranath V, Sahakian BJ, Saxena S, Singer PA, Stein DJ,. (2011) Grand challenges in global mental health. Nature 475: 27-30.
6. de Boer HM, Mula M, Sander JW,. (2008) The global burden and stigma of epilepsy. Epilepsy Behav 12: 540-546.
7. Health Action International. (2010) Database of medicine prices, availability, affordability and price components. Available at: [Accessed March 23, 2011].
8. International Monetary Fund. (2007) World Economic Outlook Database. Available at: [Accessed March 23, 2011].
9. International Monetary Fund. IMF Statistical Databases-Online Browsers and Documentation. Available at: [Accessed March 23, 2011].
10. Kesselheim AS, Stedman MR, Bubrick EJ, Gagne JJ, Misono AS, Lee JL, Brookhart MA, Avorn J, Shrank WH,. (2010) Seizure outcomes following use of generic vs. brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs 70: 605-621.
11. Kwan P, Brodie MJ,. (2004) Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. Epilepsia 45: 1141-1149.
12. Kwan P, Brodie MJ,. (2008) Early identification of refractory epilepsy. N Engl J Med 342: 314-319.
13. Laroche ML, Traore H, Merle L, Gaulier JM, Viana M, Preux PM,. (2005) Quality of phenobarbital solid-dosage forms in the urban community of Nouakchott (Mauritania). Epilepsia 46: 1293-1296.
14. Mac TL, Le VT, Vu AN, Preux PM, Ratsimbazafy V,. (2006) AEDs availability and professional practices in delivery outlets in a city center in southern Vietnam. Epilepsia 47: 330-334.
15. Management Sciences for Health (2010) International drug price indicator guide. Management Sciences for Health, Cambridge. Available at: [Accessed March 23, 2011].
16. Mbuba CK, Ngugi AK, Newton CR, Carter JA,. (2008) The epilepsy treatment gap in developing countries: a systematic review of the magnitude, causes, and intervention strategies. Epilepsia 49: 1491-1503.
17. Meinardi H, Scott RA, Reis R, Sander JW,; ILAE Commission on the Developing World. (2001) The treatment gap in epilepsy: the current situation and ways forward. Epilepsia 42: 136-149.
18. Meyer AC, Dua T, Ma J, Saxena S, Birbeck G,. (2010) Global disparities in the epilepsy treatment gap: a systematic review. Bull World Health Organ 88: 260-266.
19. Moore N, Berdaï D, Bégaud B,. (2010) Are generic drugs really inferior medicines? Clin Pharmacol Ther 88: 302-304.
20. Mu J, Liu L, Zhang Q, Si Y, Hu J, Fang J, Gao Y, He J, Li S, Wang W, Wu J, Sander JW, Zhou D,. (2011) Causes of death among people with convulsive epilepsy in rural West China: a prospective study. Neurology 77: 132-137.
21. Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW, Newton CR,. (2010) Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia 51: 883-890.
22. Sankar R, Glauser TA,. (2010) Understanding therapeutic equivalence in epilepsy. CNS Spectr 15: 112-123.
23. Scott RA, Lhatoo SD, Sander JW,. (2001) The treatment of epilepsy in developing countries: where do we go from here? Bull World Health Organ 79: 344-351.
24. Strong K, Mathers C, Leeder S, Beaglehole R,. (2005) Preventing chronic diseases: how many lives can we save? Lancet 366: 1578-1582.
25. van Mourik MS, Cameron A, Ewen M, Laing RO,. (2010) Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data. BMC Cardiovasc Disord 10: 25.
26. WHO. (2008) The global burden of disease: 2004 update. World Health Organization, Geneva. Available: [Accessed June 23, 2011]
27. WHO. (2009) Defined Daily Dose-Definition and general considerations. The WHO Collaborating Centre for Drug Statistics Methodology. 2009. Available at: [Accessed May 10, 2011].
28. WHO. (2011) Model Lists of Essential Medicines. 17th List. Available at: [Accessed May 10, 2011].
29. WHO, Health Action International. (2008) Measuring medicine prices, availability, affordability and price components. 2nd ed. WHO & Health Action International, Geneva. Available at: (Accessed March 23, 2011).
30. World Bank. (2011) Country Data. Available at: [Accessed March 23, 2011].
31. World Health Organization, International League Against Epilepsy, International Bureau for Epilepsy. (2005) Atlas: epilepsy care in the world. Available at: [Accessed December 31, 2011].
32. Yach D, Hawkes C, Epping-Jordan J, Steyn K,. (2006) Chronic diseases and risks. In, Merson MH, Black RE, Mills A, (Eds) International public health: diseases, programs, systems, and policies. 2nd ed. Jones & Bartlett Publishers Inc, Sudbury, pp. 273-322.